Valuation: Omeros Corporation

Market Cap 1.32B 1.18B 1.09B 986M 1.85B 125B 1.9B 12.96B 5.21B 66.12B 4.96B 4.86B 210B P/E 2026 *
20.2x
P/E 2027 * 17.3x
Enterprise Value 1.32B 1.18B 1.09B 986M 1.85B 125B 1.9B 12.96B 5.21B 66.12B 4.96B 4.86B 210B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 5.98x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day+2.47%
1 week+4.46%
Current month-0.92%
1 month-1.83%
3 months+45.46%
6 months+21.31%
Current year+6.38%
1 week 17.62
Extreme 17.617043
19.28
1 month 15.84
Extreme 15.845
20.24
Current year 6.7
Extreme 6.7023
21.24
1 year 6.24
Extreme 6.24
21.24
3 years 1.13
Extreme 1.13
21.24
5 years 0.92
Extreme 0.92
21.24
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap. Importance
23/09/26 Exercice

Chief Financial Officer

30,000 0.0414%
31/08/26 Exercice

General Counsel

75,000 0.1036%
27/08/26 Exercice

Director

30,000 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+2.47%+4.46%+154.81%+1,327.34% 1.29B
-2.43%-4.38%+40.32%+55.64% 62.23B
+0.61%+0.77%+11.13%+69.42% 54.92B
+0.62%+2.58%+20.96%+98.18% 55.26B
+1.61%-3.30%+22.77%+33.16% 42.59B
-1.74%-3.02%+13.83%+93.17% 41.08B
+3.22%+4.30%+227.37%+776.49% 40.33B
+0.57%+24.09%+99.46%+84.11% 33.12B
-1.09%+0.69%+14.20%+45.26% 32.61B
-4.46%+9.98%-43.92%+320.28% 23.98B
Average -0.06%+3.51%+56.09%+290.30% 38.74B
Weighted average by Cap. -0.20%+2.12%+46.18%+162.39%

Financials

2026 *2027 *
Net sales 128M 114M 105M 95.03M 178M 12.08B 183M 1.25B 502M 6.37B 479M 468M 20.2B 221M 198M 182M 165M 310M 20.97B 318M 2.17B 872M 11.07B 831M 813M 35.07B
Net income 64.97M 58.04M 53.31M 48.42M 90.93M 6.15B 93.21M 636M 256M 3.25B 244M 239M 10.3B 84.8M 75.76M 69.59M 63.2M 119M 8.03B 122M 831M 334M 4.24B 318M 311M 13.44B
Net Debt - -
Projected Income Statement - Annual - Omeros Corporation
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
03/11/26 $18.27 +2.47% 886,679
02/11/26 $17.83 -3.31% 903,499
30/10/26 $18.44 -2.69% 885,579
29/10/26 $18.95 +5.98% 3,627,920
28/10/26 $17.88 +2.23% 604,492
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Omeros Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
18.27USD
Average target price
27.50USD
Spread / Average Target
+50.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Omeros Corporation
  1. Stock Market
  2. Stocks
  3. OMER Stock